There\u2019s a sentence we hear often from founders, Clinical Affairs and Regulatory teams:<\/p>
\u201cWe have a strong device, but we\u2019re afraid of losing time.\u201d<\/strong><\/p> Not time spent working. Studies don\u2019t fail because there’s a lack of effort. At that point, teams work harder, but progress slows. Not because everything will suddenly change, but: the system is maturing, there is more focus on device lifecycle<\/strong>, there are higher expectations for robust, explainable evidence<\/strong>, there is less tolerance for studies that \u201cwork on paper\u201d but collapse under scrutiny.<\/p> The way out isn\u2019t mysterious, it has a name: a defensible evidence strategy<\/strong>.<\/p> Many projects start from features. Decision-makers start from a different question:<\/p> what changes for the patient or the clinical decision?<\/strong><\/p> When the clinical promise is vague:<\/p> When it\u2019s clear, the opposite happens: the scope narrows and what remains becomes strong.<\/p> This is one of the most expensive mistakes: endpoints are chosen because they\u2019re easy to collect, Then reality hits: yes, it\u2019s measurable, but it doesn\u2019t prove what matters.<\/p> The mature approach is the opposite:<\/p> Simple, but rarely done well.<\/p> Every innovative device carries uncertainty. A solid evidence strategy doesn\u2019t promise perfection, it does something more valuable:<\/p> Trust is built on the certainty that \u201cif things change, we know how to move.\u201d<\/em><\/p> To understand whether a project is ready, you often need a single page<\/strong>.<\/p> Not to impress, but to remove ambiguity (the real source of rework).<\/p> A solid evidence map includes:<\/p> When this page is clear, conversations get shorter and studies become defensible.<\/p> Mistake #1: confusing available data with useful data<\/strong> Mistake #2: leaving decision forks implicit<\/strong> It’s not competence that was missing: alignment was.<\/p> If you want a fast reality check, ask:<\/p> A study becomes calm<\/em> not when nothing happens but when, if something happens, you don\u2019t lose the thread.<\/p> In 2026, the difference will be who has a clearer method for building evidence that holds, even when the context evolves.<\/p>","protected":false},"excerpt":{"rendered":" There\u2019s a sentence we hear often from founders, Clinical Affairs and Regulatory teams: \u201cWe have a strong device, but we\u2019re afraid of losing time.\u201d Not time spent working.Time lost to rework, the kind that appears halfway through a study, when you realize it started\u2026 but wasn\u2019t solid enough. Studies don\u2019t fail because there’s a lack […]<\/p>\n","protected":false},"author":4,"featured_media":5028,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,18],"class_list":["post-4992","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-digital-health","tag-medical-device"],"yoast_head":"\n
Time lost to rework<\/strong>, the kind that appears halfway through a study, when you realize it started\u2026 but wasn\u2019t solid enough.<\/p>
They crack when the hard part begins and you discover that:<\/p>
Not because they\u2019re unskilled, but because there\u2019s no shared compass.<\/p>Why this matters even more in 2026<\/h2>
Innovation isn\u2019t what the device does, it\u2019s what it proves<\/h2>
A measurable endpoint isn\u2019t necessarily a useful one<\/h2>
because the technology generates them effortlessly.<\/p>Speed comes from reducing uncertainty, not ignoring it<\/h2>
That\u2019s not a flaw, it\u2019s the nature of innovation.<\/p>The page that creates clarity: the evidence map<\/h2>
Two mistakes that cost months (even with great teams)<\/h2>
Especially in digital devices: plenty of outputs, little clinical meaning.<\/p>
When deviations, outliers or context changes appear, every choice becomes a new meeting.<\/p>A final check<\/h2>